Dominik Bettinger
Overview
Explore the profile of Dominik Bettinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
2008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gairing S, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C, et al.
JHEP Rep
. 2025 Mar;
7(3):101295.
PMID: 40059970
Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly...
2.
Stockinger E, Luxenburger H, Bettinger D, Berlin C, Obwegs D, Sagar , et al.
Hepatol Commun
. 2025 Feb;
8(10).
PMID: 39992088
Background: Despite the rising prevalence of liver cirrhosis and HCC worldwide, reliable prognostic blood biomarkers are lacking. Melanoma cell adhesion molecule (MCAM) is a cell adhesion protein, and its cleavage...
3.
Sturm L, Schultheiss M, Stohr F, Labenz C, Maasoumy B, Tiede A, et al.
J Hepatol
. 2025 Feb;
PMID: 39914747
Background & Aims: The Freiburg Index of Post-TIPS Survival (FIPS) defines a high-risk group of patients with significantly reduced survival following transjugular intrahepatic portosystemic shunt (TIPS) implantation. However, the clinical...
4.
Xia D, Bai W, Wang Q, Chung J, Adhoute X, Kloeckner R, et al.
JHEP Rep
. 2025 Jan;
7(1):101216.
PMID: 39758510
Background & Aims: Current prognostic models for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) are not extensively validated and widely accepted. We aimed to develop and validate a...
5.
Surov A, Wienke A, Borggrefe J, Auer T, Gebauer B, Mahringer-Kunz A, et al.
J Cancer Res Clin Oncol
. 2024 Nov;
150(12):515.
PMID: 39614916
Purpose: The purpose of the present study was to analyze associations between different skeletal muscle quality parameters and survival in patients with hepatocellular carcinoma (HCC) undergoing treatment with transarterial chemoembolization...
6.
Reincke M, Thimme R, Bettinger D
Aliment Pharmacol Ther
. 2024 Nov;
61(2):390-391.
PMID: 39604774
No abstract available.
7.
de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, et al.
Hepatol Commun
. 2024 Nov;
8(11).
PMID: 39495153
Background: Immunotherapy-based combinations are currently the standard of care in the systemic treatment of patients with HCC. Recent studies have reported unexpectedly long survival with lenvatinib (LEN), supporting its use...
8.
Kalo E, Sturm L, Schultheiss M, Moore O, Kurup R, Gahm C, et al.
Liver Int
. 2024 Sep;
44(12):3229-3237.
PMID: 39248164
Introduction: The recently developed Freiburg Index of Post-TIPS Survival (FIPS) allows improved risk classification of patients with decompensated cirrhosis allocated to transjugular intrahepatic portosystemic shunt (TIPS) implantation. This study investigated...
9.
Mueller J, Miedtke V, Kuellmer A, Schiemer M, Bettinger D, Thimme R, et al.
Endosc Int Open
. 2024 Aug;
12(8):E989-E995.
PMID: 39184063
Endoscopic full-thickness resection (eFTR) allows treatment of "difficult to resect" lesions not amenable to conventional endoscopic methods. Efficacy and safety of the system have already been proven in numerous studies....
10.
Muller L, Mahringer-Kunz A, Auer T, Fehrenbach U, Gebauer B, Haubold J, et al.
JHEP Rep
. 2024 Aug;
6(8):101125.
PMID: 39139458
Background & Aims: Body composition assessment (BCA) parameters have recently been identified as relevant prognostic factors for patients with hepatocellular carcinoma (HCC). Herein, we aimed to investigate the role of...